Literature DB >> 17211556

Serum protease inhibitor concentrations and total antitrypsin activity in diabetic and non-diabetic children during adolescence.

B Lisowska-Myjak1, J Pachecka, B Kaczyńska, G Miszkurka, K Kadziela.   

Abstract

The aim of the study was the assessment of the concentrations and establishment of mutual relationships between three main protease inhibitors: alpha-1-antitrypsin (AAT), alpha-2-macroglobulin (alpha-2-M) and antithrombin-III (AT-III), and of the total trypsin inhibitory capacity (TIC) in the serum of diabetic and non-diabetic children during adolescence. Forty-nine children (24 girls and 25 boys) with type 1 diabetes mellitus and 24 non-diabetic children (13 girls and 11 boys) were divided according to the Tanner scale into three groups: pre-, peri- and post-pubertal. The concentrations of AAT, alpha-2-M and AT-III were determined by the radial immunodiffusion method on NOR-Partigen plates (Dade-Behring), while TIC was determined by the method using BAPNA as substrate. Means and medians of serum AAT [1.55 g/l, 1.40 (95% confidence interval, 1.42-1.68), respectively] and TIC [10.6 mg trypsin/100 ml, 10.3 (95% CI, 9.5-11.7)] in diabetic children were lower than means and medians of AAT [1.81 g/l, 1.60 (95% CI 1.55-2.07), respectively] and TIC [12.5 mg trypsin/100 ml, 13.2 (95% CI, 10.9-14.1)] in non-diabetic children. A comparison of variables between Tanner groups shows an increasing trend of AAT concentration in diabetic children and a decreasing trend of TIC in non-diabetic subjects. In contrast to pre- and peri-puberty, no correlations were found in the postpubertal period between the studied parameters, either in diabetic or non-diabetic patients. Hyperglycaemia and the duration of diabetes were found to have a significant association with alpha-2-M and AT-III concentrations, but not with AAT serum concentrations. The concentrations and correlations between serum protease inhibitors in diabetic children during adolescence are disrupted compared with non-diabetic children. Taking into account the unfavourable consequences of vascular complications resulting from serum trypsin inhibitor changes and protease- antiprotease imbalance, diabetic children are at greater risk of this occurring during adolescence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17211556     DOI: 10.1007/s00592-006-0220-8

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  16 in total

Review 1.  Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes.

Authors:  Gabriella Fleixo-Lima; Hilla Ventura; Michal Medini; Liliana Bar; Pnina Strauss; Eli C Lewis
Journal:  J Diabetes Sci Technol       Date:  2014-08-25

Review 2.  Targeting Innate Immunity for Type 1 Diabetes Prevention.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

3.  α-1-antitrypsin gene delivery reduces inflammation, increases T-regulatory cell population size and prevents islet allograft rejection.

Authors:  Galit Shahaf; Hadas Moser; Eyal Ozeri; Mark Mizrahi; Avishag Abecassis; Eli C Lewis
Journal:  Mol Med       Date:  2011-06-09       Impact factor: 6.354

Review 4.  Expanding the clinical indications for α(1)-antitrypsin therapy.

Authors:  Eli C Lewis
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

5.  Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice.

Authors:  Sandhya Subramanian; Galit Shahaf; Eyal Ozeri; Lisa M Miller; Arthur A Vandenbark; Eli C Lewis; Halina Offner
Journal:  Metab Brain Dis       Date:  2011-03-25       Impact factor: 3.584

6.  Alpha 1-antitrypsin activity is markedly decreased in Wegener's granulomatosis.

Authors:  Ali Mota; Abbas Sahebghadam Lotfi; Ahmad-Reza Jamshidi; Saeed Najavand
Journal:  Rheumatol Int       Date:  2013-04-19       Impact factor: 2.631

7.  Effect of recombinant α1-antitrypsin Fc-fused (AAT-Fc)protein on the inhibition of inflammatory cytokine production and streptozotocin-induced diabetes.

Authors:  Siyoung Lee; Youngmin Lee; Kwangwon Hong; Jaewoo Hong; Suyoung Bae; Jida Choi; Hyunjhung Jhun; Areum Kwak; Eunsom Kim; Seunghyun Jo; Charles A Dinarello; Soohyun Kim
Journal:  Mol Med       Date:  2013-05-20       Impact factor: 6.354

8.  Diabetes Impairs Cellular Cholesterol Efflux From ABCA1 to Small HDL Particles.

Authors:  Yi He; Graziella E Ronsein; Chongren Tang; Gail P Jarvik; W Sean Davidson; Vishal Kothari; Hyun D Song; Jere P Segrest; Karin E Bornfeldt; Jay W Heinecke
Journal:  Circ Res       Date:  2020-08-21       Impact factor: 17.367

9.  Reduced 25(OH) Vitamin D Association with Lower Alpha-1-Antitrypsin Blood Levels in Type 2 Diabetic Patients.

Authors:  Virginia M Lindley; Kamal Bhusal; Laura Huning; Steven N Levine; Sushil K Jain
Journal:  J Am Coll Nutr       Date:  2020-04-10       Impact factor: 3.571

10.  Differential denaturation of serum proteome reveals a significant amount of hidden information in complex mixtures of proteins.

Authors:  Vincenzo Verdoliva; Cinzia Senatore; Maria Letizia Polci; Stefania Rossi; Martina Cordella; Giuseppe Carlucci; Paolo Marchetti; Giancarlo Antonini-Cappellini; Antonio Facchiano; Daniela D'Arcangelo; Francesco Facchiano
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.